{"gene":"KIR2DS4","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2009,"finding":"KIR2DS4 binds specifically to subsets of C1+ and C2+ HLA-C alleles and to HLA-A*11 (specifically A*1102 but not A*1101); the proline-valine motif at positions 71-72 (shared with KIR3DL2 via gene conversion) is largely responsible for this unique HLA class I specificity, as demonstrated by site-directed swap mutagenesis. Crystal structure revealed displacement of contact loop L2 and altered bonding potential at positions 71-72 compared to KIR2DL.","method":"Site-directed swap mutagenesis, NK cell activation assay (NKL cells with HLA ligands), X-ray crystallography","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus mutagenesis plus functional NK activation assay in a single study","pmids":["19858347"],"is_preprint":false},{"year":2002,"finding":"A 22 bp deletion in exon 5 of KIR2DS4 causes a frameshift, truncating the protein with loss of transmembrane and cytoplasmic domains, predicting a secreted/soluble form (KIR1D) rather than a membrane-bound receptor.","method":"cDNA cloning and sequencing, deletion-specific PCR probe","journal":"Tissue antigens","confidence":"High","confidence_rationale":"Tier 1-2 — direct sequence characterization replicated across multiple studies","pmids":["12445308"],"is_preprint":false},{"year":2007,"finding":"The deleted KIR2DS4 variant (22 bp deletion) encodes a soluble, secreted protein not anchored to the cell membrane, confirmed by in vitro cell line expression studies and in vivo protein expression studies; full-length KIR2DS4 is membrane-bound and functional.","method":"In vitro cell line model expression, in vivo protein expression studies, PCR-SSOP typing","journal":"Human immunology","confidence":"High","confidence_rationale":"Tier 2 — direct protein expression characterization with both in vitro and in vivo evidence, replicated from earlier sequencing work","pmids":["17321903"],"is_preprint":false},{"year":2004,"finding":"KIR2DS4 can interact with a non-MHC class I ligand expressed on melanoma cell lines and primary melanoma (in addition to HLA-Cw4), and site-directed mutagenesis shows that different amino acid residues mediate recognition of this novel ligand versus HLA-Cw4.","method":"Binding assays, site-directed mutagenesis, NK cell functional assays with HLA-C-transfected cells and melanoma lines","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 — site-directed mutagenesis plus functional NK assays, single lab, novel ligand not further characterized","pmids":["15265913"],"is_preprint":false},{"year":2019,"finding":"KIR2DS4 has a strong preference for 9-mer peptides carrying tryptophan at position 8 (p8) presented by HLA-C*05:01; this peptide-HLA complex is sufficient to activate primary KIR2DS4+ NK cells independently of other activating receptors and prior NK licensing. A conserved bacterial RecA epitope with this motif from multiple human pathogens (Helicobacter, Chlamydia, Brucella, Campylobacter) activates KIR2DS4+ NK cells.","method":"Primary NK cell activation assay (degranulation), peptide-HLA binding, functional assays with HLA-C*05:01+ cells expressing specific peptides","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (binding, degranulation assay, defined peptide epitope), primary NK cells used, single lab","pmids":["31138701"],"is_preprint":false},{"year":2016,"finding":"KIR2DS4 is expressed by ~45% of uterine NK cells, and triggering of KIR2DS4 on uterine NK cells leads to secretion of GM-CSF, XCL1, CCL1, and other chemokines that promote placental trophoblast invasion.","method":"Flow cytometry (surface expression), cytokine secretion assay (120-cytokine screen), functional stimulation of uNK cells","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 — direct protein expression with flow cytometry, functional receptor triggering with broad cytokine profiling","pmids":["27815424"],"is_preprint":false},{"year":2015,"finding":"KIR2DS4 can induce uptake of CCR7 (trogocytosis) by KIR2DS4+NKG2A+ NK cell clones after interacting with HLA-Cw4 and HLA-Cw6 on CCR7+ target cells; this activation is not always sufficient to override NKG2A inhibition.","method":"Functional trogocytosis assay, cytotoxicity assay with HLA-C-transfected cells, NK cell clones","journal":"Journal of immunology research","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional assay with NK clones and transfected targets, single lab","pmids":["25961063"],"is_preprint":false},{"year":2014,"finding":"KIR2DS4-positive NK cells from HIV-1-infected individuals are enriched for polyfunctional activity (degranulation, IFN-γ and MIP-1β secretion) compared to KIR2DS4-negative NK cells, suggesting KIR2DS4 surface expression drives a pro-inflammatory NK cell state.","method":"Flow cytometry-based NK cell functional assays (degranulation, intracellular cytokine staining) stratified by KIR2DS4 surface expression","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — direct ex vivo functional readout stratified by receptor expression, single lab","pmids":["24901871"],"is_preprint":false},{"year":2018,"finding":"Acute aerobic exercise reduces promoter DNA methylation of KIR2DS4 in NK cells (at CpG sites within the KIR2DS4 promoter CpG island containing three cytosine sites), with a corresponding increase in KIR2DS4 gene expression; high expression correlated with low methylation of exercise-altered CpGs.","method":"Targeted deep-amplicon bisulfite sequencing for promoter methylation, qRT-PCR for expression, flow cytometry for NK subset analysis","journal":"International journal of sports medicine","confidence":"Medium","confidence_rationale":"Tier 2 — direct epigenetic and expression measurements linked mechanistically, single lab","pmids":["30508863"],"is_preprint":false},{"year":2012,"finding":"KIR2DS4 promoter contains a CpG island with three cytosine sites; increased promoter hypomethylation in NK cells after hematopoietic cell transplantation is associated with elevated KIR2DS4 mRNA expression, suggesting promoter methylation regulates KIR2DS4 transcription.","method":"Sodium bisulfite sequencing of promoter CpG island, mRNA quantitative PCR","journal":"Human immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct methylation-expression correlation with bisulfite sequencing, single lab","pmids":["22939905"],"is_preprint":false}],"current_model":"KIR2DS4 is an activating NK cell receptor whose full-length form binds subsets of HLA-C alleles and HLA-A*11 via a proline-valine motif at positions 71-72 (introduced by gene conversion from KIR3DL2), with peptide specificity for Trp at position 8 of HLA-C*05:01-presented peptides including bacterial RecA epitopes; a common 22 bp exon 5 deletion causes a frameshift yielding a secreted, non-functional soluble form (KIR1D), while the membrane-bound receptor activates NK cells to degranulate and secrete pro-inflammatory cytokines/chemokines (GM-CSF, XCL1, CCL1, IFN-γ, MIP-1β), and can also trigger trogocytosis of CCR7 from target cells; its transcription is regulated by promoter CpG methylation."},"narrative":{"teleology":[{"year":2002,"claim":"Identification of a 22-bp exon 5 deletion established that the most common KIR2DS4 allele encodes a truncated, secreted protein (KIR1D) rather than a membrane-bound activating receptor, resolving why many individuals carrying KIR2DS4 lack functional surface expression.","evidence":"cDNA cloning and deletion-specific PCR across multiple individuals","pmids":["12445308"],"confidence":"High","gaps":["Whether the soluble KIR1D form has any biological activity was not determined","Frequency of deletion versus full-length alleles across diverse populations was not fully catalogued"]},{"year":2004,"claim":"Discovery that KIR2DS4 recognizes a non-MHC class I ligand on melanoma cells, with distinct residues mediating this interaction versus HLA-Cw4 binding, revealed dual-ligand recognition capacity.","evidence":"Binding assays and site-directed mutagenesis with melanoma lines and HLA-C-transfected cells","pmids":["15265913"],"confidence":"Medium","gaps":["The non-MHC ligand was not molecularly identified","Not independently replicated in a second laboratory","Physiological relevance of non-MHC ligand recognition remains undefined"]},{"year":2007,"claim":"Confirmation at the protein level that full-length KIR2DS4 is membrane-anchored and functional while the deletion variant is secreted solidified the functional dichotomy between allelic forms.","evidence":"In vitro and in vivo protein expression studies with PCR-SSOP typing","pmids":["17321903"],"confidence":"High","gaps":["Whether soluble KIR1D competes with membrane KIR2DS4 for ligand was not tested"]},{"year":2009,"claim":"Structural and mutagenesis work revealed that KIR2DS4 binds HLA-C subsets and HLA-A*11 through a proline-valine motif at positions 71–72 acquired from KIR3DL2 by gene conversion, with crystal structure showing displacement of loop L2 — explaining its unique and broader HLA specificity compared to other KIR2D receptors.","evidence":"X-ray crystallography, site-directed swap mutagenesis, NKL cell activation assays","pmids":["19858347"],"confidence":"High","gaps":["How KIR2DS4 discriminates between A*1101 and A*1102 at the structural level was not resolved","Contribution of peptide cargo to binding was not addressed"]},{"year":2012,"claim":"Demonstration that KIR2DS4 promoter CpG methylation inversely correlates with mRNA expression established an epigenetic mechanism governing receptor transcription, addressing how stochastic KIR expression patterns arise.","evidence":"Bisulfite sequencing of the three-CpG promoter island coupled with qPCR in post-transplant NK cells","pmids":["22939905"],"confidence":"Medium","gaps":["Causal relationship between demethylation and transcription was not formally demonstrated","Transcription factor binding at demethylated CpGs was not identified"]},{"year":2014,"claim":"Linking KIR2DS4 surface expression to polyfunctional NK activity (degranulation, IFN-γ, MIP-1β) in HIV-infected individuals provided direct evidence that the receptor drives a pro-inflammatory NK cell state in vivo.","evidence":"Ex vivo flow cytometry-based degranulation and intracellular cytokine assays stratified by KIR2DS4 expression","pmids":["24901871"],"confidence":"Medium","gaps":["Whether KIR2DS4 directly recognized HIV-infected cells or responded to altered HLA expression was not determined","Single cohort study"]},{"year":2015,"claim":"Discovery that KIR2DS4 engagement triggers trogocytosis of CCR7 from HLA-C+ target cells revealed a non-cytolytic effector mechanism, though this activation could be overridden by NKG2A inhibitory signaling.","evidence":"Trogocytosis and cytotoxicity assays using NK clones with HLA-C-transfected targets","pmids":["25961063"],"confidence":"Medium","gaps":["Physiological consequence of CCR7 trogocytosis on NK cell migration was not tested","Limited to clonal NK populations"]},{"year":2016,"claim":"Profiling of uterine NK cells showed KIR2DS4 triggering induces secretion of GM-CSF, XCL1, and CCL1 that promote trophoblast invasion, establishing a tissue-specific reproductive function for this activating receptor.","evidence":"Flow cytometry, 120-cytokine screen, and functional stimulation of uterine NK cells","pmids":["27815424"],"confidence":"High","gaps":["Specific HLA ligand on trophoblasts engaging KIR2DS4 was not defined","In vivo validation of trophoblast invasion promotion not performed"]},{"year":2019,"claim":"Identification of peptide selectivity for Trp at p8 of HLA-C*05:01-bound peptides, including conserved bacterial RecA epitopes, demonstrated that KIR2DS4 functions as a pathogen-sensing receptor with fine peptide discrimination — resolving the long-standing question of whether activating KIR can detect microbial antigens.","evidence":"Primary NK cell degranulation assays with defined peptide-HLA complexes; bacterial epitope screening","pmids":["31138701"],"confidence":"High","gaps":["Whether KIR2DS4 peptide selectivity extends to viral epitopes was not tested","Structural basis for p8-Trp preference not determined crystallographically"]},{"year":null,"claim":"Key unresolved questions include the identity of the non-MHC ligand on melanoma, the structural basis for peptide selectivity, whether soluble KIR1D has immunomodulatory function, and how KIR2DS4 signaling integrates with other activating and inhibitory KIR in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["Non-MHC ligand remains molecularly unidentified","No crystal structure of KIR2DS4 bound to peptide-HLA complex","Functional role of soluble KIR1D untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,4,5,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,5,6,7]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,2]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,4,5,7]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,5,6]}],"complexes":[],"partners":["HLA-C","HLA-A","CCR7"],"other_free_text":[]},"mechanistic_narrative":"KIR2DS4 is an activating killer-cell immunoglobulin-like receptor on NK cells that recognizes HLA class I molecules and triggers pro-inflammatory effector functions including degranulation and cytokine secretion. The full-length receptor binds subsets of HLA-C alleles and HLA-A*11 through a proline-valine motif at positions 71–72 acquired by gene conversion from KIR3DL2, with crystal structure revealing displacement of contact loop L2 that reshapes ligand specificity; it also exhibits peptide selectivity for tryptophan at position 8 of HLA-C*05:01-presented peptides, enabling recognition of conserved bacterial RecA epitopes from multiple human pathogens [PMID:19858347, PMID:31138701]. A common 22-bp deletion in exon 5 causes a frameshift yielding a secreted, non-functional soluble form (KIR1D) lacking transmembrane and cytoplasmic domains, while the membrane-bound form activates NK cells to secrete GM-CSF, XCL1, CCL1, IFN-γ, and MIP-1β and can induce trogocytosis of CCR7 from target cells [PMID:12445308, PMID:17321903, PMID:27815424, PMID:25961063]. Transcription of KIR2DS4 is regulated by CpG methylation within a three-CpG-site promoter island, with hypomethylation correlating with increased expression [PMID:22939905]."},"prefetch_data":{"uniprot":{"accession":"P43632","full_name":"Killer cell immunoglobulin-like receptor 2DS4","aliases":["CD158 antigen-like family member I","Natural killer-associated transcript 8","NKAT-8","P58 natural killer cell receptor clones CL-39/CL-17","p58 NK receptor CL-39/CL-17"],"length_aa":304,"mass_kda":33.6,"function":"Receptor on natural killer (NK) cells for HLA-C alleles. Does not inhibit the activity of NK cells","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P43632/entry"},"depmap":{"release":"DepMap","has_data":false,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KIR2DS4"},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KIR2DS4","total_profiled":1310},"omim":[{"mim_id":"620778","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, SHORT CYTOPLASMIC TAIL, 1; KIR3DS1","url":"https://www.omim.org/entry/620778"},{"mim_id":"604955","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, TWO DOMAINS, SHORT CYTOPLASMIC TAIL, 4; KIR2DS4","url":"https://www.omim.org/entry/604955"},{"mim_id":"604946","title":"KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR, THREE DOMAINS, LONG CYTOPLASMIC TAIL, 1; KIR3DL1","url":"https://www.omim.org/entry/604946"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Not detected","tissue_distribution":"Not detected","driving_tissues":[],"url":"https://www.proteinatlas.org/search/KIR2DS4"},"hgnc":{"alias_symbol":["cl-39","KKA3","nkat8","CD158I"],"prev_symbol":[]},"alphafold":{"accession":"P43632","domains":[{"cath_id":"2.60.40.10","chopping":"24-122","consensus_level":"high","plddt":94.1703,"start":24,"end":122},{"cath_id":"2.60.40.10","chopping":"127-223","consensus_level":"high","plddt":95.8896,"start":127,"end":223}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P43632","model_url":"https://alphafold.ebi.ac.uk/files/AF-P43632-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P43632-F1-predicted_aligned_error_v6.png","plddt_mean":81.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KIR2DS4","jax_strain_url":"https://www.jax.org/strain/search?query=KIR2DS4"},"sequence":{"accession":"P43632","fasta_url":"https://rest.uniprot.org/uniprotkb/P43632.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P43632/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P43632"}},"corpus_meta":[{"pmid":"19858347","id":"PMC_19858347","title":"KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C.","date":"2009","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19858347","citation_count":200,"is_preprint":false},{"pmid":"12445308","id":"PMC_12445308","title":"A common KIR2DS4 deletion variant in the human that predicts a soluble KIR molecule analogous to the KIR1D molecule observed in the rhesus monkey.","date":"2002","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/12445308","citation_count":112,"is_preprint":false},{"pmid":"15265913","id":"PMC_15265913","title":"MHC class I-independent recognition of NK-activating receptor KIR2DS4.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15265913","citation_count":84,"is_preprint":false},{"pmid":"17321903","id":"PMC_17321903","title":"Studies on the expression of the deleted KIR2DS4*003 gene product and distribution of KIR2DS4 deleted and nondeleted versions in different populations.","date":"2007","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17321903","citation_count":83,"is_preprint":false},{"pmid":"27815424","id":"PMC_27815424","title":"Activating KIR2DS4 Is Expressed by Uterine NK Cells and Contributes to Successful Pregnancy.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27815424","citation_count":77,"is_preprint":false},{"pmid":"31138701","id":"PMC_31138701","title":"Human NK cell receptor KIR2DS4 detects a conserved bacterial epitope presented by HLA-C.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31138701","citation_count":68,"is_preprint":false},{"pmid":"21216870","id":"PMC_21216870","title":"Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples.","date":"2011","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/21216870","citation_count":47,"is_preprint":false},{"pmid":"15219381","id":"PMC_15219381","title":"Investigation of killer cell immunoglobulin-like receptor gene diversity: II. KIR2DS4.","date":"2004","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15219381","citation_count":40,"is_preprint":false},{"pmid":"25715101","id":"PMC_25715101","title":"The HLA-C*04: 01/KIR2DS4 gene combination and human leukocyte antigen alleles with high population frequency drive rate of HIV disease progression.","date":"2015","source":"AIDS (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25715101","citation_count":33,"is_preprint":false},{"pmid":"21596150","id":"PMC_21596150","title":"Expression of activating KIR2DS2 and KIR2DS4 genes after hematopoietic cell transplantation: relevance to cytomegalovirus infection.","date":"2011","source":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/21596150","citation_count":30,"is_preprint":false},{"pmid":"24901871","id":"PMC_24901871","title":"KIR2DS4 promotes HIV-1 pathogenesis: new evidence from analyses of immunogenetic data and natural killer cell function.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24901871","citation_count":29,"is_preprint":false},{"pmid":"20062104","id":"PMC_20062104","title":"The impact of KIR2DS4 alleles and the expression of KIR in the development of acute GVHD after unrelated allogeneic hematopoietic SCT.","date":"2010","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/20062104","citation_count":25,"is_preprint":false},{"pmid":"19859704","id":"PMC_19859704","title":"KIR3DL1/S1 genotypes and KIR2DS4 allelic variants in the AB KIR genotypes are associated with Plasmodium-positive individuals in malaria infection.","date":"2010","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19859704","citation_count":21,"is_preprint":false},{"pmid":"25961063","id":"PMC_25961063","title":"Uptake of CCR7 by KIR2DS4⁺ NK cells is induced upon recognition of certain HLA-C alleles.","date":"2015","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/25961063","citation_count":19,"is_preprint":false},{"pmid":"12697308","id":"PMC_12697308","title":"Mass spectrometric analyses of CL(39), CL(41) and H(1), H(2), H(3) confirm identity with fetidin and lysenin produced by earthworm leukocytes.","date":"2003","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12697308","citation_count":19,"is_preprint":false},{"pmid":"24239756","id":"PMC_24239756","title":"KIR2DS4 allelic variants: Differential effects on in utero and intrapartum HIV-1 mother-to-child transmission.","date":"2013","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/24239756","citation_count":16,"is_preprint":false},{"pmid":"22128817","id":"PMC_22128817","title":"Association of KIR2DS4 and its variant KIR1D with syphilis in a Chinese Han population.","date":"2011","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22128817","citation_count":15,"is_preprint":false},{"pmid":"27998801","id":"PMC_27998801","title":"The impact of KIR2DS4 gene on clinical outcome after hematopoietic stem cell transplantation.","date":"2016","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27998801","citation_count":14,"is_preprint":false},{"pmid":"25069714","id":"PMC_25069714","title":"Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment.","date":"2014","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/25069714","citation_count":14,"is_preprint":false},{"pmid":"37850268","id":"PMC_37850268","title":"HLA-DPB1*13:01 associates with enhanced, and KIR2DS4*001 with diminished protection from developing severe COVID-19.","date":"2023","source":"HLA","url":"https://pubmed.ncbi.nlm.nih.gov/37850268","citation_count":12,"is_preprint":false},{"pmid":"21554925","id":"PMC_21554925","title":"T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines.","date":"2011","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21554925","citation_count":11,"is_preprint":false},{"pmid":"17257315","id":"PMC_17257315","title":"Diversity of the killer cell immunoglobulin-like receptor gene KIR2DS4 in the Chinese population.","date":"2007","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/17257315","citation_count":10,"is_preprint":false},{"pmid":"30796344","id":"PMC_30796344","title":"Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30796344","citation_count":9,"is_preprint":false},{"pmid":"30508863","id":"PMC_30508863","title":"Acute Exercise Increases the Expression of KIR2DS4 by Promoter Demethylation in NK Cells.","date":"2018","source":"International journal of sports medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30508863","citation_count":8,"is_preprint":false},{"pmid":"31899050","id":"PMC_31899050","title":"Positive association of Bx genotype, KIR2L5, KIR2DS5 and full-length KIR2DS4 with the risk of meningioma.","date":"2019","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31899050","citation_count":8,"is_preprint":false},{"pmid":"28734803","id":"PMC_28734803","title":"Distribution of KIR genes and KIR2DS4 gene variants in two Mexican Mestizo populations.","date":"2017","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28734803","citation_count":7,"is_preprint":false},{"pmid":"34277872","id":"PMC_34277872","title":"Rheumatoid Arthritis Susceptibility Is Associated with the KIR2DS4-Full of Killer-Cell Immunoglobulin-Like Receptor Genes in the Lur Population of Iran.","date":"2021","source":"Reports of biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34277872","citation_count":6,"is_preprint":false},{"pmid":"31751561","id":"PMC_31751561","title":"KIR2DS4, KIR2DL2, and KIR2DS4del are linked with basaloid tumors, lymph node metastasis, advanced stage and metastatic risk in head and neck squamous cell carcinoma.","date":"2019","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31751561","citation_count":6,"is_preprint":false},{"pmid":"24659081","id":"PMC_24659081","title":"Investigation of deletion of 22pb in KIR2DS4 gene in a population of southern Brazil.","date":"2014","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/24659081","citation_count":2,"is_preprint":false},{"pmid":"39540437","id":"PMC_39540437","title":"The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression.","date":"2024","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/39540437","citation_count":2,"is_preprint":false},{"pmid":"15130674","id":"PMC_15130674","title":"Hypothetical soluble KIR2DS4 natural killer cell receptor molecule does not associate with successful ageing in the Irish.","date":"2004","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/15130674","citation_count":2,"is_preprint":false},{"pmid":"28186587","id":"PMC_28186587","title":"[Genetic polymorphisms of KIR2DS4 gene among ethnic Hans from southern China].","date":"2017","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28186587","citation_count":2,"is_preprint":false},{"pmid":"32594584","id":"PMC_32594584","title":"The impact of donor full-length KIR2DS4 in the development of acute and chronic GVHD after unrelated allogeneic HSCT.","date":"2020","source":"Pediatric transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/32594584","citation_count":2,"is_preprint":false},{"pmid":"37150297","id":"PMC_37150297","title":"KIR2DS4 and Its Variant KIR1D in KIR-AA Genotype Donors Showed Differential Survival Impact in Patients with Lymphoid Disease after HLA-Matched Unrelated Hematopoietic Stem Cell Transplantation.","date":"2023","source":"Transplantation and cellular therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37150297","citation_count":1,"is_preprint":false},{"pmid":"22939905","id":"PMC_22939905","title":"KIR2DS2 and KIR2DS4 promoter hypomethylation patterns in patients undergoing hematopoietic cell transplantation (HCT).","date":"2012","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22939905","citation_count":1,"is_preprint":false},{"pmid":"21223724","id":"PMC_21223724","title":"[The impact of KIR2DS4 gene on clinical outcomes of HLA matched unrelated allo-HSCT].","date":"2010","source":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","url":"https://pubmed.ncbi.nlm.nih.gov/21223724","citation_count":1,"is_preprint":false},{"pmid":"18549650","id":"PMC_18549650","title":"[Construction and identification of Kir2ds4 RNAi lentiviral vector].","date":"2008","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/18549650","citation_count":0,"is_preprint":false},{"pmid":"35773759","id":"PMC_35773759","title":"[Establishment of sequence-based typing assay for KIR2DS4 gene and identification of a new allele KIR2DS4*016].","date":"2022","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35773759","citation_count":0,"is_preprint":false},{"pmid":"41230735","id":"PMC_41230735","title":"Genetically predicted KIR2DS4 mediate the association between gut microbe K10 and osteoporosis fractures: A mediation Mendelian randomization study.","date":"2025","source":"PM & R : the journal of injury, function, and rehabilitation","url":"https://pubmed.ncbi.nlm.nih.gov/41230735","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.12.03.626612","title":"High KIR diversity in Uganda and Botswana children living with HIV","date":"2024-12-07","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.03.626612","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":21970,"output_tokens":2445,"usd":0.051292},"stage2":{"model":"claude-opus-4-6","input_tokens":5770,"output_tokens":2419,"usd":0.133988},"total_usd":0.18528,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"KIR2DS4 binds specifically to subsets of C1+ and C2+ HLA-C alleles and to HLA-A*11 (specifically A*1102 but not A*1101); the proline-valine motif at positions 71-72 (shared with KIR3DL2 via gene conversion) is largely responsible for this unique HLA class I specificity, as demonstrated by site-directed swap mutagenesis. Crystal structure revealed displacement of contact loop L2 and altered bonding potential at positions 71-72 compared to KIR2DL.\",\n      \"method\": \"Site-directed swap mutagenesis, NK cell activation assay (NKL cells with HLA ligands), X-ray crystallography\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus mutagenesis plus functional NK activation assay in a single study\",\n      \"pmids\": [\"19858347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A 22 bp deletion in exon 5 of KIR2DS4 causes a frameshift, truncating the protein with loss of transmembrane and cytoplasmic domains, predicting a secreted/soluble form (KIR1D) rather than a membrane-bound receptor.\",\n      \"method\": \"cDNA cloning and sequencing, deletion-specific PCR probe\",\n      \"journal\": \"Tissue antigens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct sequence characterization replicated across multiple studies\",\n      \"pmids\": [\"12445308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The deleted KIR2DS4 variant (22 bp deletion) encodes a soluble, secreted protein not anchored to the cell membrane, confirmed by in vitro cell line expression studies and in vivo protein expression studies; full-length KIR2DS4 is membrane-bound and functional.\",\n      \"method\": \"In vitro cell line model expression, in vivo protein expression studies, PCR-SSOP typing\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein expression characterization with both in vitro and in vivo evidence, replicated from earlier sequencing work\",\n      \"pmids\": [\"17321903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"KIR2DS4 can interact with a non-MHC class I ligand expressed on melanoma cell lines and primary melanoma (in addition to HLA-Cw4), and site-directed mutagenesis shows that different amino acid residues mediate recognition of this novel ligand versus HLA-Cw4.\",\n      \"method\": \"Binding assays, site-directed mutagenesis, NK cell functional assays with HLA-C-transfected cells and melanoma lines\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — site-directed mutagenesis plus functional NK assays, single lab, novel ligand not further characterized\",\n      \"pmids\": [\"15265913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KIR2DS4 has a strong preference for 9-mer peptides carrying tryptophan at position 8 (p8) presented by HLA-C*05:01; this peptide-HLA complex is sufficient to activate primary KIR2DS4+ NK cells independently of other activating receptors and prior NK licensing. A conserved bacterial RecA epitope with this motif from multiple human pathogens (Helicobacter, Chlamydia, Brucella, Campylobacter) activates KIR2DS4+ NK cells.\",\n      \"method\": \"Primary NK cell activation assay (degranulation), peptide-HLA binding, functional assays with HLA-C*05:01+ cells expressing specific peptides\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (binding, degranulation assay, defined peptide epitope), primary NK cells used, single lab\",\n      \"pmids\": [\"31138701\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"KIR2DS4 is expressed by ~45% of uterine NK cells, and triggering of KIR2DS4 on uterine NK cells leads to secretion of GM-CSF, XCL1, CCL1, and other chemokines that promote placental trophoblast invasion.\",\n      \"method\": \"Flow cytometry (surface expression), cytokine secretion assay (120-cytokine screen), functional stimulation of uNK cells\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein expression with flow cytometry, functional receptor triggering with broad cytokine profiling\",\n      \"pmids\": [\"27815424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"KIR2DS4 can induce uptake of CCR7 (trogocytosis) by KIR2DS4+NKG2A+ NK cell clones after interacting with HLA-Cw4 and HLA-Cw6 on CCR7+ target cells; this activation is not always sufficient to override NKG2A inhibition.\",\n      \"method\": \"Functional trogocytosis assay, cytotoxicity assay with HLA-C-transfected cells, NK cell clones\",\n      \"journal\": \"Journal of immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay with NK clones and transfected targets, single lab\",\n      \"pmids\": [\"25961063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"KIR2DS4-positive NK cells from HIV-1-infected individuals are enriched for polyfunctional activity (degranulation, IFN-γ and MIP-1β secretion) compared to KIR2DS4-negative NK cells, suggesting KIR2DS4 surface expression drives a pro-inflammatory NK cell state.\",\n      \"method\": \"Flow cytometry-based NK cell functional assays (degranulation, intracellular cytokine staining) stratified by KIR2DS4 surface expression\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct ex vivo functional readout stratified by receptor expression, single lab\",\n      \"pmids\": [\"24901871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Acute aerobic exercise reduces promoter DNA methylation of KIR2DS4 in NK cells (at CpG sites within the KIR2DS4 promoter CpG island containing three cytosine sites), with a corresponding increase in KIR2DS4 gene expression; high expression correlated with low methylation of exercise-altered CpGs.\",\n      \"method\": \"Targeted deep-amplicon bisulfite sequencing for promoter methylation, qRT-PCR for expression, flow cytometry for NK subset analysis\",\n      \"journal\": \"International journal of sports medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct epigenetic and expression measurements linked mechanistically, single lab\",\n      \"pmids\": [\"30508863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KIR2DS4 promoter contains a CpG island with three cytosine sites; increased promoter hypomethylation in NK cells after hematopoietic cell transplantation is associated with elevated KIR2DS4 mRNA expression, suggesting promoter methylation regulates KIR2DS4 transcription.\",\n      \"method\": \"Sodium bisulfite sequencing of promoter CpG island, mRNA quantitative PCR\",\n      \"journal\": \"Human immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct methylation-expression correlation with bisulfite sequencing, single lab\",\n      \"pmids\": [\"22939905\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KIR2DS4 is an activating NK cell receptor whose full-length form binds subsets of HLA-C alleles and HLA-A*11 via a proline-valine motif at positions 71-72 (introduced by gene conversion from KIR3DL2), with peptide specificity for Trp at position 8 of HLA-C*05:01-presented peptides including bacterial RecA epitopes; a common 22 bp exon 5 deletion causes a frameshift yielding a secreted, non-functional soluble form (KIR1D), while the membrane-bound receptor activates NK cells to degranulate and secrete pro-inflammatory cytokines/chemokines (GM-CSF, XCL1, CCL1, IFN-γ, MIP-1β), and can also trigger trogocytosis of CCR7 from target cells; its transcription is regulated by promoter CpG methylation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"KIR2DS4 is an activating killer-cell immunoglobulin-like receptor on NK cells that recognizes HLA class I molecules and triggers pro-inflammatory effector functions including degranulation and cytokine secretion. The full-length receptor binds subsets of HLA-C alleles and HLA-A*11 through a proline-valine motif at positions 71–72 acquired by gene conversion from KIR3DL2, with crystal structure revealing displacement of contact loop L2 that reshapes ligand specificity; it also exhibits peptide selectivity for tryptophan at position 8 of HLA-C*05:01-presented peptides, enabling recognition of conserved bacterial RecA epitopes from multiple human pathogens [PMID:19858347, PMID:31138701]. A common 22-bp deletion in exon 5 causes a frameshift yielding a secreted, non-functional soluble form (KIR1D) lacking transmembrane and cytoplasmic domains, while the membrane-bound form activates NK cells to secrete GM-CSF, XCL1, CCL1, IFN-γ, and MIP-1β and can induce trogocytosis of CCR7 from target cells [PMID:12445308, PMID:17321903, PMID:27815424, PMID:25961063]. Transcription of KIR2DS4 is regulated by CpG methylation within a three-CpG-site promoter island, with hypomethylation correlating with increased expression [PMID:22939905].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of a 22-bp exon 5 deletion established that the most common KIR2DS4 allele encodes a truncated, secreted protein (KIR1D) rather than a membrane-bound activating receptor, resolving why many individuals carrying KIR2DS4 lack functional surface expression.\",\n      \"evidence\": \"cDNA cloning and deletion-specific PCR across multiple individuals\",\n      \"pmids\": [\"12445308\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the soluble KIR1D form has any biological activity was not determined\", \"Frequency of deletion versus full-length alleles across diverse populations was not fully catalogued\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Discovery that KIR2DS4 recognizes a non-MHC class I ligand on melanoma cells, with distinct residues mediating this interaction versus HLA-Cw4 binding, revealed dual-ligand recognition capacity.\",\n      \"evidence\": \"Binding assays and site-directed mutagenesis with melanoma lines and HLA-C-transfected cells\",\n      \"pmids\": [\"15265913\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The non-MHC ligand was not molecularly identified\", \"Not independently replicated in a second laboratory\", \"Physiological relevance of non-MHC ligand recognition remains undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Confirmation at the protein level that full-length KIR2DS4 is membrane-anchored and functional while the deletion variant is secreted solidified the functional dichotomy between allelic forms.\",\n      \"evidence\": \"In vitro and in vivo protein expression studies with PCR-SSOP typing\",\n      \"pmids\": [\"17321903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether soluble KIR1D competes with membrane KIR2DS4 for ligand was not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Structural and mutagenesis work revealed that KIR2DS4 binds HLA-C subsets and HLA-A*11 through a proline-valine motif at positions 71–72 acquired from KIR3DL2 by gene conversion, with crystal structure showing displacement of loop L2 — explaining its unique and broader HLA specificity compared to other KIR2D receptors.\",\n      \"evidence\": \"X-ray crystallography, site-directed swap mutagenesis, NKL cell activation assays\",\n      \"pmids\": [\"19858347\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How KIR2DS4 discriminates between A*1101 and A*1102 at the structural level was not resolved\", \"Contribution of peptide cargo to binding was not addressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstration that KIR2DS4 promoter CpG methylation inversely correlates with mRNA expression established an epigenetic mechanism governing receptor transcription, addressing how stochastic KIR expression patterns arise.\",\n      \"evidence\": \"Bisulfite sequencing of the three-CpG promoter island coupled with qPCR in post-transplant NK cells\",\n      \"pmids\": [\"22939905\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal relationship between demethylation and transcription was not formally demonstrated\", \"Transcription factor binding at demethylated CpGs was not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linking KIR2DS4 surface expression to polyfunctional NK activity (degranulation, IFN-γ, MIP-1β) in HIV-infected individuals provided direct evidence that the receptor drives a pro-inflammatory NK cell state in vivo.\",\n      \"evidence\": \"Ex vivo flow cytometry-based degranulation and intracellular cytokine assays stratified by KIR2DS4 expression\",\n      \"pmids\": [\"24901871\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether KIR2DS4 directly recognized HIV-infected cells or responded to altered HLA expression was not determined\", \"Single cohort study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that KIR2DS4 engagement triggers trogocytosis of CCR7 from HLA-C+ target cells revealed a non-cytolytic effector mechanism, though this activation could be overridden by NKG2A inhibitory signaling.\",\n      \"evidence\": \"Trogocytosis and cytotoxicity assays using NK clones with HLA-C-transfected targets\",\n      \"pmids\": [\"25961063\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological consequence of CCR7 trogocytosis on NK cell migration was not tested\", \"Limited to clonal NK populations\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Profiling of uterine NK cells showed KIR2DS4 triggering induces secretion of GM-CSF, XCL1, and CCL1 that promote trophoblast invasion, establishing a tissue-specific reproductive function for this activating receptor.\",\n      \"evidence\": \"Flow cytometry, 120-cytokine screen, and functional stimulation of uterine NK cells\",\n      \"pmids\": [\"27815424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific HLA ligand on trophoblasts engaging KIR2DS4 was not defined\", \"In vivo validation of trophoblast invasion promotion not performed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of peptide selectivity for Trp at p8 of HLA-C*05:01-bound peptides, including conserved bacterial RecA epitopes, demonstrated that KIR2DS4 functions as a pathogen-sensing receptor with fine peptide discrimination — resolving the long-standing question of whether activating KIR can detect microbial antigens.\",\n      \"evidence\": \"Primary NK cell degranulation assays with defined peptide-HLA complexes; bacterial epitope screening\",\n      \"pmids\": [\"31138701\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether KIR2DS4 peptide selectivity extends to viral epitopes was not tested\", \"Structural basis for p8-Trp preference not determined crystallographically\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the non-MHC ligand on melanoma, the structural basis for peptide selectivity, whether soluble KIR1D has immunomodulatory function, and how KIR2DS4 signaling integrates with other activating and inhibitory KIR in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Non-MHC ligand remains molecularly unidentified\", \"No crystal structure of KIR2DS4 bound to peptide-HLA complex\", \"Functional role of soluble KIR1D untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 4, 5, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 5, 6, 7]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 4, 5, 7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 5, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"HLA-C\",\n      \"HLA-A\",\n      \"CCR7\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}